Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Todd D Green

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|March 12, 2015
Anaphylaxis management before and after implementation of guidelines in the pediatric emergency departmentShilpa H Desai, Kwonho Jeong, Jacob D Kattan, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 1, 2020
Post hoc analysis of epicutaneous immunotherapy for peanut allergy phase 3 results: Relevance for exposure through restaurant mealsBenjamin C Remington, Dianne E Campbell, Todd D Green, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 16, 2022
The Impact of Allergy Specialty Care on Health Care Utilization Among Peanut Allergy Children in the United StatesMatthew Greenhawt, Elissa M Abrams, Joseph M Chalil, et al.
Allergy|June 2, 2021
Predicted number of peanut-allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevanceBenjamin C Remington, Stef J Koppelman, Todd D Green, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 6, 2020
Improvements in eliciting dose across baseline sensitivities following 12 months of epicutaneous immunotherapy (EPIT) in peanut-allergic children aged 4 to 11 yearsMatthew Greenhawt, Edwin H Kim, Dianne E Campbell, et al.
Allergy|September 28, 2024
Epicutaneous immunotherapy for the treatment of peanut allergyMayuran Ravindran, Hugh A Sampson, Edwin H Kim, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 20, 2020
Commercial claims costs related to health care resource use associated with a diagnosis of peanut allergyMarcus Shaker, Joseph M Chalil, Oth Tran, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 26, 2020
Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE StudiesAudrey DunnGalvin, David M Fleischer, Dianne E Campbell, et al.
Case Reports in Immunology|November 8, 2014
Chronic granulomatous disease presenting as aseptic ascites in a 2-year-old childJ F Moreau, John A Ozolek, P Ling Lin, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|February 3, 2020
Unmet needs of children with peanut allergy: Aligning the risks and the evidenceEdmond S Chan, Chitra Dinakar, Erika Gonzales-Reyes, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
The Journal of Allergy and Clinical Immunology. in Practice|March 12, 2015
Anaphylaxis management before and after implementation of guidelines in the pediatric emergency departmentShilpa H Desai, Kwonho Jeong, Jacob D Kattan, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 1, 2020
Post hoc analysis of epicutaneous immunotherapy for peanut allergy phase 3 results: Relevance for exposure through restaurant mealsBenjamin C Remington, Dianne E Campbell, Todd D Green, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 16, 2022
The Impact of Allergy Specialty Care on Health Care Utilization Among Peanut Allergy Children in the United StatesMatthew Greenhawt, Elissa M Abrams, Joseph M Chalil, et al.
Allergy|June 2, 2021
Predicted number of peanut-allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevanceBenjamin C Remington, Stef J Koppelman, Todd D Green, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 6, 2020
Improvements in eliciting dose across baseline sensitivities following 12 months of epicutaneous immunotherapy (EPIT) in peanut-allergic children aged 4 to 11 yearsMatthew Greenhawt, Edwin H Kim, Dianne E Campbell, et al.
Allergy|September 28, 2024
Epicutaneous immunotherapy for the treatment of peanut allergyMayuran Ravindran, Hugh A Sampson, Edwin H Kim, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 20, 2020
Commercial claims costs related to health care resource use associated with a diagnosis of peanut allergyMarcus Shaker, Joseph M Chalil, Oth Tran, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 26, 2020
Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE StudiesAudrey DunnGalvin, David M Fleischer, Dianne E Campbell, et al.
Case Reports in Immunology|November 8, 2014
Chronic granulomatous disease presenting as aseptic ascites in a 2-year-old childJ F Moreau, John A Ozolek, P Ling Lin, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|February 3, 2020
Unmet needs of children with peanut allergy: Aligning the risks and the evidenceEdmond S Chan, Chitra Dinakar, Erika Gonzales-Reyes, et al.
Pageof 5